Last reviewed · How we verify
estradiol mustard
estradiol mustard is a estradiol mustard drug. It is currently in unknown development.
Estradiol mustard is thought to work by binding to and modifying estrogen receptors, although the exact mechanism is unclear.
Estradiol mustard is a small molecule drug in the estradiol mustard class, but specific details about its development, ownership, and commercial status are not available. Its target and mechanism of action are also unknown. As a result, there is limited information available about its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to determine its clinical utility and safety profile. Without more information, it is difficult to assess its commercial status or key safety considerations.
At a glance
| Generic name | estradiol mustard |
|---|---|
| Drug class | estradiol mustard |
| Target | Estrogen receptor |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's cells have locks on them, and estradiol mustard has a key that fits into those locks. When it binds to the locks, it can turn on or off certain cellular processes, but the exact way it does this is still being studied. This process can affect how cells grow and divide, which is important for treating certain diseases.
Approved indications
Common side effects
Key clinical trials
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer (PHASE2)
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (PHASE1,PHASE2)
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (PHASE1,PHASE2)
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (PHASE1,PHASE2)
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (PHASE1,PHASE2)
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (PHASE1,PHASE2)
- Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy (PHASE2)
- Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- estradiol mustard CI brief — competitive landscape report
- estradiol mustard updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about estradiol mustard
What is estradiol mustard?
How does estradiol mustard work?
What drug class is estradiol mustard in?
What development phase is estradiol mustard in?
What does estradiol mustard target?
Related
- Drug class: All estradiol mustard drugs
- Target: All drugs targeting Estrogen receptor
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing